• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pneumagen touts non-human results for intranasal drug treatment for COVID-19

March 8, 2021 By Sean Whooley

PneumagenPneumagen announced today that study results show the effectiveness of its Neumifil intranasal drug in treating COVID-19.

St. Andrews, Scotland-based Pneumagen’s Neumafil, a viral intranasal drug for protection against respiratory tract infections (RTIs), was used on a hamster model of COVID-19 infection and displayed effectiveness as it significantly reduced clinical signs and weight loss in animals infected with SARS-CoV-2, according to a news release.

Additionally, Pneumagen scientists at the University of St. Andrews confirmed high-affinity bonding to COVID-19 spike proteins from the Wuhan, United Kingdom and South African variants, as well as the ACE2 receptor which is used by the virus to infect the host.

Neumifil is a first-in-class carbohydrate-binding module (mCBMs) generated from Pneumagen’s GlycoTarge platform. The drug is being developed to treat RTIs caused by influenza viruses, RSV and coronaviruses such as SARS-CoV-2.

“This exciting data confirms Neumifil’s potential as a treatment against variant strains of COVID-19,” Pneumagen CEO Douglas Thomson said in the release. “Neumifil, our universal pan-viral intranasal product, targets glycans to provide both prophylaxis and treatment for COVID-19, and other emerging viruses with pandemic potential. We are preparing for a Phase I clinical study in mid-2021.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, Pneumagen

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS